Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | LITESPARK-029: belzutifan with fulvestrant in ER+/HER2- breast cancer

Bora Lim • 12 Dec 2024
SABCS 2024
Breast Cancer Belzutifan Everolimus Exemestane Fulvestrant
LITESPARK-029

Bora Lim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase II LITESPARK-029 trial (NCT06428396) of belzutifan, a HIF-2α inhibitor, with fulvestrant versus everolimus with fulvestrant or exemestane in patients with ER+/HER2- unresectable or metastatic breast cancer. Primary endpoints include progression-free survival (PFS) and secondary objectives include overall survival and clinical benefit. This trial aims to address resistance mechanisms and improve outcomes in advanced disease. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bora Lim

HIF-2α as an alternate therapeutic target in ER+ breast cancer
1:17
HIF-2α as an alternate therapeutic target in ER+ breast cancer
Bora Lim • 12 Dec 2024
Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC
2:46
Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC
Bora Lim • 12 Dec 2024
Highlights at SABCS 2021 for basic science and early-phase clinical trials
1:32
Highlights at SABCS 2021 for basic science and early-phase clinical trials
Bora Lim • 9 Dec 2021
Single-cell genomics and proteogenomics in cancer
1:49
Single-cell genomics and proteogenomics in cancer
Bora Lim • 9 Dec 2021

Related Videos

Recommendations for low-dose tamoxifen in pre- and postmenopausal women with breast cancer
0:55
Recommendations for low-dose tamoxifen in pre- and postmenopausal women with breast cancer
Andrea De Censi • 29 May 2026
Pre-pectoral IBBR and oncologic safety following mastectomy
1:20
Pre-pectoral IBBR and oncologic safety following mastectomy
Walter Weber • 30 May 2026
Low-dose tamoxifen could prevent breast cancer in at-risk young premenopausal women
0:45
Low-dose tamoxifen could prevent breast cancer in at-risk young premenopausal women
Andrea De Censi • 29 May 2026
Results from the PREPEC trial support pre-pectoral positioning for IBBR following mastectomy
0:48
Results from the PREPEC trial support pre-pectoral positioning for IBBR following mastectomy
Walter Weber • 30 May 2026
The content of VJOncology is intended for healthcare professionals